Effects of Selective and Nonselective Beta-blockade on Platelet Aggregation in Patients With Acute Coronary Syndrome
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Platelet aggregation
研究概览
简要总结
The Investigators will test the hypothesis that nonselective beta-blockers would have a more pronounced effect on platelet aggregation than selective beta-blockers in patients with acute coronary syndrome treated with dual anti platelet therapy.
详细描述
In patients with acute coronary syndrome (ACS) beta-blockers are recommended for secondary prevention. It is known that catecholamine levels can potentiate platelet reactivity and beta-blocking agents may also affect platelet aggregation. This effect is mainly mediated by adrenergic receptors on platelets. This suggests that nonselective beta-blockers would have a more pronounced effect on platelet aggregation than selective beta-blockers. However, little is known about the effect of beta-blockers on platelet aggregation in patients with cardiovascular disease and, to date, nothing is known in the setting of ACS.
The aim of the present study is to evaluate the effect of selective and nonselective beta-blockers on platelet aggregation in ACS patients treated with dual anti platelet therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acute Coronary Syndrome
- •Current dual anti platelet treatment with acetylsalicylic acid and Ticagrelor
排除标准
- •ongoing prasugrel, ticlopidine or clopidogrel therapy
- •Creatinine Clearance < 30 ml/min/1.73mm2
- •Moderate to severe anemia Hemoglobin < 10 mg/dl
- •Platelet count >600000/mm3 or <150000/mm3 or hematocrit >50% or <25%
- •concomitant neoplastic or immune-mediated pathologies
- •severe pulmonary pathologies
- •contraindication to beta blocker therapy.
研究组 & 干预措施
Carvedilol
Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume carvedilol.
干预措施: Carvedilol (Drug)
Metoprolol
Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume metoprolol.
干预措施: Metoprolol (Drug)
结局指标
主要结局
Platelet aggregation
时间窗: 30 days
Platelet aggregation induced by epinephrine is measured by Light Transmission Aggregometry (LTA)
次要结局
- 30-days clinical events(30 days)
- 30-days platelet aggregation(30 days)
研究者
Giovanni Esposito
MD, PhD
Federico II University